Peptide Atlas · Peptide

Relamorelin

Relamorelin (RM-131) is a selective ghrelin receptor agonist; in a 12-week phase 2B study in 393 people with diabetic gastroparesis, vomiting frequency fell 75% from baseline, but not significantly more than on placebo.

emerging

provisional
PubChem 44251769
2 citations
0 discussions
0 followers
BIM-28131
RM-131
pentapeptide ghrelin agonist

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Relamorelin. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Relamorelin increased antral contractions in healthy volunteers	emerging	pmid 27283792
Relamorelin in diabetic gastroparesis (phase 2B): vomiting reduction not different from placebo	emerging	pmid 28760384

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.